Indications
Visceral leishmaniasis Miltefosine is an antileishmanial drug indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment of:
Visceral leishmaniasis due to Leishmania donovani.
Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis.
Mucosal leishmaniasis due to Leishmania braziliensis.
Dosage And Administration
Administer with food to ameliorate gastrointestinal adverse reactions.
30 to 44 kg: one 50 mg capsule twice daily for 28 consecutive days.
45 kg or greater: one 50 mg capsule three times daily for 28 consecutive days.
Side Effects
Adverse reactions occurring in ≥2% of patients include nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated creatinine.
Precautions And Warnings
Embryo-Fetal Toxicity. Do not use in pregnant women. Obtain a urine or serum pregnancy test prior to initiation of therapy. Advise use of effective contraception in females of reproductive potential.
Reproductive effects. Miltefosine caused testicular atrophy and impaired fertility in male rats and impaired fertility in female rats. Advise patients of reproductive toxicities in animal studies and that the potential effects on human fertility have not been adequately evaluated.
Renal Effects. Monitor serum creatinine during therapy and for 4 weeks after end of therapy.
Hepatic Effects. Monitor transaminases and bilirubin during therapy.
Gastrointestinal Effects. Encourage fluid intake.
Thrombocytopenia. Monitor platelet count during therapy for visceral leishmaniasis.
Absorption of Oral Contraceptives. Advise use of alternative method of contraception if vomiting and/or diarrhea occur.
Stevens-Johnson syndrome. Discontinue miltefosine.
Pregnancy And Lactation
Pregnancy: Miltefosine should not be used during pregnancy. Obtain a urine or serum pregnancy test in females of reproductive potential prior to prescribing.Nursing Mothers: Discontinue drug or nursing depending on the importance of drug to the mother. Avoid breastfeeding for 5 months after Miltefosine therapy.Females and Males of Reproductive Potential: Advise females to use effective contraception during therapy and for 5 months after therapy. Advise patients of reproductive toxicities in animals, and that the potential for impaired fertility in humans has not been adequately evaluated